__timestamp | Eli Lilly and Company | Novo Nordisk A/S |
---|---|---|
Tuesday, January 1, 2019 | 122369084370 | 915808743862.0308 |
Wednesday, January 1, 2020 | 153244924560 | 992801077492.3201 |
Friday, January 1, 2021 | 250521319860.00003 | 1681508787391.9998 |
Saturday, January 1, 2022 | 329891098240 | 2129286754102.3198 |
Sunday, January 1, 2023 | 524733508519.99994 | 3139248089387.3394 |
Cracking the code
In the past five years, the pharmaceutical giants Novo Nordisk and Eli Lilly have shown remarkable growth in market capitalization. Novo Nordisk, a leader in diabetes care, has seen its market cap soar by over 240%, reaching a peak in 2023. Meanwhile, Eli Lilly, known for its innovative treatments, has experienced a substantial increase of approximately 330% during the same period.
In 2019, Novo Nordisk's market cap was nearly eight times that of Eli Lilly. However, by 2023, Eli Lilly has significantly closed the gap, with its market cap now about one-sixth of Novo Nordisk's. This shift highlights the dynamic nature of the pharmaceutical industry and the competitive landscape between these two powerhouses. As they continue to innovate and expand, investors and industry watchers should keep a close eye on their future trajectories.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters